Most Read Articles
Roshini Claire Anthony, 06 Oct 2020

Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.

Pearl Toh, 15 Nov 2020
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.

Romilkimab delivers in diffuse cutaneous systemic sclerosis

15 Oct 2020

Romilkimab, a novel bispecific immunoglobulin-G4 antibody that binds and neutralizes interleukin (IL)-4/IL-13, shows promise in the treatment of diffuse cutaneous systemic sclerosis (dcSSc), producing significant reduction in skin fibrosis, according to data from a phase II trial.

Ninety-seven adult dcSSc patients with or without immunosuppressive background therapy were randomized to receive either romilkimab (n=48) or placebo (n=49) for 24 weeks.

The primary endpoint of change in modified Rodnan skin score (mRSS) at week 24 was significantly greater with the study drug than with placebo (–4.76 vs –2.45; difference, –2.31, 95 percent confidence interval, –4.32 to –0.31; p=0.0291).

There were no significant differences observed in the secondary endpoints of forced vital capacity (–10 mL with romilkimab vs –80 mL with placebo; p=0.10), diffusing lung capacity for carbon monoxide (–0.12 vs –0.27, respectively; p=0.14), and physical/functional disability (mean Health Assessment Questionnaire-Disability Index score, –0.09 vs –0.12, respectively; p=0.40).

Treatment-emergent adverse event were comparable between romilkimab and placebo (80 percent vs 84 percent), with most events being mild to moderate in severity and rarely leading to discontinuations (three overall).

There were two deaths documented, one due to scleroderma renal crisis in the active treatment group and the other due to cardiomyopathy in the placebo group, but neither was considered treatment related. There were no cardiac safety signals detected with romilkimab.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 06 Oct 2020

Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.

Pearl Toh, 15 Nov 2020
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.